Concord Drugs Limited has announced strong financial performance for the quarter ended December 31, 2025, demonstrating robust revenue growth and sustained profitability across both standalone and consolidated operations.

Financial Performance Overview

The company delivered impressive results for Q3FY26, with significant improvements in key financial metrics compared to the corresponding period last year.

Nine-Month Performance

For the nine months ended December 31, 2025, the company maintained strong momentum with substantial revenue growth and improved profitability.

Consolidated Results

The consolidated financial results showed similar positive trends, reflecting the overall strength of the company's operations:

• Total Revenue: ₹1,698.75 lakhs for Q3FY26
• Net Profit: ₹21.69 lakhs for the quarter
• Nine-month Revenue: ₹4,087.24 lakhs
• Nine-month Net Profit: ₹52.69 lakhs

Capital Structure and Equity

The company's financial position remained stable with a paid-up capital of ₹1,317.50 lakhs and other equity of ₹3,482.21 lakhs. The earnings per share for the nine-month period stood at ₹0.40 on both basic and diluted basis.

Board Approval and Compliance

The unaudited financial results were reviewed and recommended by the Audit Committee before being approved by the Board of Directors at their meeting held on February 14, 2026. The results have been filed with stock exchanges in compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The detailed quarterly financial results are available on the company's website at www.concorddrugs.in and on the stock exchange website at www.bseindia.com .

Concord Drugs Limited has submitted its Independent Auditor's Review Report on both consolidated and standalone unaudited quarterly and year-to-date financial results for the quarter ended December 31, 2025. The review was conducted by Pundarikashyam and Associates, Chartered Accountants, in compliance with SEBI Regulation 33.

Corrigendum to Financial Results

The company issued a corrigendum on February 16, 2026, addressing an inadvertent omission in its original Q3FY26 financial results disclosure submitted on February 14, 2026. The update specifically relates to the complete implementation details of Labour Codes that were not fully reflected in the initial disclosure.

Labour Codes Implementation Update

The corrected disclosure provides comprehensive details about the Government of India's consolidation of 29 existing labour legislations into four unified Labour Codes. These codes became effective from November 21, 2025, though supporting rules are yet to be notified.

Auditor Review Details

The independent auditor's review was conducted for both consolidated and standalone financial results covering the quarter ended December 31, 2025, and year-to-date results from April 1, 2025, to December 31, 2025.

Subsidiary Performance

The consolidated results include performance from subsidiary Proton Remedies Private Limited. The subsidiary's financial contribution for the nine-month period shows steady operational performance.

Fund Raising and Utilization

The company disclosed details of its recent preferential issue and confirmed no deviation in fund utilization. The fundraising was completed in November 2025 with proper regulatory compliance.

Regulatory Compliance

The auditor confirmed that the financial statements comply with Indian Accounting Standard 34 (Ind AS 34) for Interim Financial Reporting and SEBI regulations. The company reported no outstanding defaults on loans and debt securities for the quarter ended December 31, 2025. The company continues to monitor the finalisation of Central and State Rules and clarifications from the Government regarding other aspects of the New Labour Code, having estimated and accounted for incremental liability for employees which is not material to the financial results.